Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study-Reference-Cited by-同舟云学术

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Published:2020-11 Issue:11 Volume:21 Page:1478-1488
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Guo Christina,Chénard-Poirier Maxime,Roda Desamparados,de Miguel Maria,Harris Samuel J,Candilejo Irene Moreno,Sriskandarajah Priya,Xu Wen,Scaranti Mariana,Constantinidou Anastasia,King Jenny,Parmar Mona,Turner Alison J,Carreira Suzanne,Riisnaes Ruth,Finneran Laura,Hall Emma,Ishikawa Yuji,Nakai Kiyohiko,Tunariu Nina,Basu Bristi,Kaiser Martin,Lopez Juanita Suzanne,Minchom Anna,de Bono Johann S,Banerji Udai

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. MAP kinase signalling pathways in cancer;Dhillon;Oncogene,2007

2. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma;Walker;J Clin Oncol,2015

3. RAS-targeted therapies: is the undruggable drugged?;Moore;Nat Rev Drug Discov,2020

4. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC);Blumenschein;Ann Oncol,2015

5. Targeting protein prenylation for cancer therapy;Berndt;Nat Rev Cancer,2011

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1H-benzo[d]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the “Clamp” Strategy;Journal of Medicinal Chemistry;2024-08-21

2. Advances in Personalized Oncology;Cancers;2024-08-16

3. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas;Gynecologic Oncology;2024-08

4. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

5. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-26